Efficacy comparison of intravesical instillation of gemcitabin and bacillus calmette guerin in patients with high-risk non-muscle invasive bladder cancer

Abstract

Objective \nTo compare clinical efficacy of intravesical instillation of gemcitabine(GEM) and bacillus calmette guerin(BCG) for high-risk non-muscle invasive bladder cancer(NMIBC). \n \n \nMethods \nFrom September 2015 to June 2017, clinical data of 208 NMIBC patients underwent transurethral resection of bladder tumor were prospective analyzed.All patients were assigned into GEM group(n=135)and BCG group(n=73). Recurrence, progression and side effects between two groups were followed up. \n \n \nResults \nRecurrence rate of BCG group was significantly lower than GEM group(38.5% vs.21.9%, P=0.015). However, there was no significant difference(P=0.257) in tumor progression between GEM (20.0%) group and BCG group (13.7%), and adverse effects of GEM was significantly lower than BCG group (14.1% vs.27.4%, P=0.019). \n \n \nConclusions \nBCG is superior to GEM in preventing recurrence, but there is no significant difference in tumor progression, adverse effects of BCG is higher than GEM group. \n \n \nKey words: \nUrinary Bladder Neoplasms;\xa0BCG Vaccine;\xa0Chemotherapy, Cancer, Regional Perfusion